WEED (BUDZ) 10-Q 17 Aug 22 2022 Q2 Quarterly report Financial data

Cover

Cover - shares	6 Months Ended
	Jun. 30, 2022	Aug. 12, 2022
Cover [Abstract]
Document Type	10-Q
Amendment Flag	false
Document Quarterly Report	true
Document Transition Report	false
Document Period End Date	Jun. 30, 2022
Document Fiscal Period Focus	Q2
Document Fiscal Year Focus	2022
Current Fiscal Year End Date	--12-31
Entity File Number	333-219922
Entity Registrant Name	WEED, Inc.
Entity Central Index Key	0001393772
Entity Tax Identification Number	83-0452269
Entity Incorporation, State or Country Code	NV
Entity Address, Address Line One	4920 N. Post Trail
Entity Address, City or Town	Tucson
Entity Address, State or Province	AZ
Entity Address, Postal Zip Code	85750
City Area Code	520
Local Phone Number	818-8582
Entity Current Reporting Status	Yes
Entity Interactive Data Current	Yes
Entity Filer Category	Non-accelerated Filer
Entity Small Business	true
Entity Emerging Growth Company	false
Entity Shell Company	false
Entity Common Stock, Shares Outstanding		122,602,685

CONSOLIDATED BALANCE SHEETS (Un

CONSOLIDATED BALANCE SHEETS (Unaudited) - USD ($)	Jun. 30, 2022	Dec. 31, 2021
CURRENT ASSETS:
Cash	$ 821,094	$ 19,654
Accounts Receivable	822	822
Inventory	82,000
Prepaid expenses	18,268	21,442
TOTAL CURRENT ASSETS	922,184	41,918
Land	372,069	383,027
Building	1,109,931	1,977,973
Computers & Equipment	167,715	79,915
Leasehold improvements		5,000
Property and equipment, gross	1,649,715	2,445,915
Less: Accumulated depreciation	(367,175)	(569,184)
Property and equipment, net	1,282,540	1,876,731
Goodwill	480,200	0
Trademark	50,000	50,000
Intangible assets, gross	530,200	50,000
Less: Accumulated amortization	(10,584)	(9,424)
Intangible assets, net	519,616	40,576
ROU asset	50,139
TOTAL ASSETS	2,774,479	1,959,225
CURRENT LIABILITIES
Accounts payable	117,944	245,857
Accrued expense	24,900	16,500
Accrued officer compensation	423,250	365,750
Accrued interest	39,448	50,887
Notes payable, related parties	897,661	596,401
Notes payable - in default	0	65,607
Lease Liability	50,139
Due to officer	723	723
TOTAL CURRENT LIABILITIES	1,554,065	1,341,725
TOTAL LIABILITIES	1,554,065	1,341,725
STOCKHOLDERS’ EQUITY (DEFICIT)
Common stock, $0.001 par value, 200,000,000 authorized, 122,602,685 and 119,222,685 issued and outstanding, respectively	122,603	119,223
Additional paid-in capital	83,689,148	82,976,493
Subscription payable	606,250	356,250
Accumulated deficit	(83,197,575)	(82,832,901)
Accumulated other comprehensive loss:
Foreign currency translation	(12)	(1,565)
TOTAL STOCKHOLDERS’ EQUITY (DEFICIT)	1,220,414	617,500
TOTAL LIABILITIES & STOCKERHOLDERS’ EQUITY (DEFICIT)	$ 2,774,479	$ 1,959,225

CONSOLIDATED BALANCE SHEETS (_2

CONSOLIDATED BALANCE SHEETS (Unaudited) (Parenthetical) - $ / shares	Jun. 30, 2022	Dec. 31, 2021
Statement of Financial Position [Abstract]
Common Stock, Par or Stated Value Per Share	$ 0.001	$ 0.001
Common Stock, Shares Authorized	200,000,000	200,000,000
Common Stock, Shares, Issued	122,602,685	119,222,685
Common Stock, Shares, Outstanding	122,602,685	119,222,685

CONSOLIDATED STATEMENTS OF OPER

CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS (Unaudited) - USD ($)	3 Months Ended		6 Months Ended
	Jun. 30, 2022	Jun. 30, 2021	Jun. 30, 2022	Jun. 30, 2021
Income Statement [Abstract]
REVENUE
OPERATING EXPENSES
General and administrative expenses	175,818	76,765	312,608	527,481
Professional fees	202,649	1,103,244	562,050	1,574,856
Depreciation & amortization	28,846	27,603	63,795	60,961
Total operating expenses	407,313	1,207,612	938,453	2,163,298
NET OPERATING LOSS	(407,313)	(1,207,612)	(938,453)	(2,163,298)
OTHER INCOME (EXPENSE)
Interest expense	(19,438)	(17,233)	(65,519)	(26,800)
Other income (expense)	13,275	(2,918)	(475)	(9,409)
Gain on disposal of fixed assets	639,773		639,773
TOTAL OTHER INCOME (EXPENSE)	633,610	(20,151)	573,779	(36,209)
NET (LOSS) INCOME	226,297	(1,227,763)	(364,674)	(2,199,507)
OTHER COMPREHENSIVE INCOME (LOSS)	2,309	75	1,553	(487)
COMPREHENSIVE LOSS	$ 228,606	$ (1,227,688)	$ (363,121)	$ (2,199,994)
WEIGHTED AVERAGE NUMBER OF COMMON SHARES
Outstanding - basic and fully diluted	121,911,366	116,077,630	120,924,895	115,152,022
Net loss per share - basic and fully diluted	$ 0.002	$ (0.01)	$ (0.003)	$ (0.02)

CONSOLIDATED STATEMENTS OF CHAN

CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS' EQUITY (DEFICIT) (Unaudited) - USD ($)	Common Stock [Member]	Additional Paid-in Capital [Member]	Subscription Payable [Member]	Retained Earnings [Member]	AOCI Attributable to Parent [Member]	Total
Beginning balance, value at Dec. 31, 2020	$ 113,373	$ 80,403,267	$ 356,250	$ (79,991,051)	$ (120)	$ 881,719
Shares, Outstanding, Beginning Balance at Dec. 31, 2020	113,372,685
Common stock sold for cash	$ 2,200	557,800				560,000
Stock Issued During Period, Shares, New Issues	2,200,000
Common stock issued for services	$ 3,650	1,999,200				2,002,850
Stock Issued During Period, Shares, Issued for Services	3,650,000
Imputed Interest on RP Loans		16,226				16,226
Net income				(2,841,850)		(2,841,850)
Other comprehensive income, net					(1,445)	(1,445)
Ending balance, value at Dec. 31, 2021	$ 119,223	82,976,493	356,250	(82,832,901)	(1,565)	617,500
Shares, Outstanding, Ending Balance at Dec. 31, 2021	119,222,685
Common stock sold for cash	$ 200	29,800				30,000
Stock Issued During Period, Shares, New Issues	200,000
Common stock issued for services	$ 1,410	312,790				314,200
Stock Issued During Period, Shares, Issued for Services	1,410,000
Imputed Interest on RP Loans		9,127				9,127
Net income				(590,971)		(590,971)
Other comprehensive income, net					(756)	(756)
Ending balance, value at Mar. 31, 2022	$ 120,833	83,328,210	356,250	(83,423,872)	(2,321)	379,100
Shares, Outstanding, Ending Balance at Mar. 31, 2022	120,832,685
Beginning balance, value at Dec. 31, 2021	$ 119,223	82,976,493	356,250	(82,832,901)	(1,565)	617,500
Shares, Outstanding, Beginning Balance at Dec. 31, 2021	119,222,685
Common stock sold for cash						40,000
Stock Issued During Period, Shares, New Issues	300,000
Common stock issued for services						457,800
Stock Issued During Period, Shares, Issued for Services	2,080,000
Imputed Interest on RP Loans						18,235
Net income						(364,674)
Stock Issued During Period, Shares, Acquisitions	1,000,000
Ending balance, value at Jun. 30, 2022	$ 122,603	83,689,148	606,250	(83,197,575)	(12)	1,220,414
Shares, Outstanding, Ending Balance at Jun. 30, 2022	122,602,685
Beginning balance, value at Mar. 31, 2022	$ 120,833	83,328,210	356,250	(83,423,872)	(2,321)	379,100
Shares, Outstanding, Beginning Balance at Mar. 31, 2022	120,832,685
Common stock sold for cash	$ 100	9,900				10,000
Stock Issued During Period, Shares, New Issues	100,000
Common stock issued for services	$ 670	142,930	50,000			193,600
Stock Issued During Period, Shares, Issued for Services	670,000
Imputed Interest on RP Loans		9,108				9,108
Net income				226,297		226,297
Other comprehensive income, net					2,309	2,309
Stock issuance for acquistion of Hempriical Genetics	$ 1,000	199,000	200,000			400,000
Stock Issued During Period, Shares, Acquisitions	1,000,000
Ending balance, value at Jun. 30, 2022	$ 122,603	$ 83,689,148	$ 606,250	$ (83,197,575)	$ (12)	$ 1,220,414
Shares, Outstanding, Ending Balance at Jun. 30, 2022	122,602,685

CONSOLIDATED STATEMENTS OF CASH

CONSOLIDATED STATEMENTS OF CASH FLOWS (Unaudited) - USD ($)	6 Months Ended
	Jun. 30, 2022	Jun. 30, 2021
CASH FLOWS FROM OPERATING ACTIVITIES
Net loss	$ (364,674)	$ (2,199,507)
Adjustments to reconcile to net loss to net cash used in operating activities:
Depreciation and amortization	63,795	60,961
Debt discount amortization	43,241
Gain on disposal of fixed asset	(639,773)
Imputed Interet on RP Loans	18,235	16,226
Estimated fair value of stock based compensation
Estimated fair value of shares issued for services	507,800	1,743,350
Decrease (increase) in assets
Inventory
Prepaid expenses and deposits	3,174	6,989
Deposits - related party		(60,000)
Increase (decrease) in liabilities
Accounts Payable	(127,912)	12,433
Accrued expenses	54,461	40,611
NET CASH USED IN OPERATING ACTIVITIES	(441,653)	(378,937)
CASH FLOWS FROM INVESTING ACTIVITIES
Purchases of property and equipment		(3,734)
Proceeds from disposal of fixed asset	1,257,037
NET CASH PROVIDED BY (USED IN) INVESTING ACTIVITIES	1,257,037	(3,734)
CASH FLOWS FROM FINANCING ACTIVITIES
Stock payable		30,000
Proceeds from notes payable - related party
Proceeds from the sale of common stock	40,000	380,000
Proceeds from notes payable	464,978	38,500
Repayments on notes payable - related party	(445,591)
Repayments on notes payable	(74,884)	(39,369)
NET CASH PROVIDED BY FINANCING ACTIVITIES	(15,497)	409,131
NET CHANGE IN CASH	799,887	26,460
EFFECT OF EXCHANGE RATE ON CASH	1,553	(487)
CASH, BEGINNING OF PERIOD	19,654	12,629
CASH, END OF PERIOD	821,094	38,602
SUPPLEMENTAL DISCLOSURE OF CASH FLOW INFORMATION
Income taxes
Interest paid
Acquistion of Hemprical Genetics with common stock and note payable	$ 650,000

Nature of Business and Signific

Nature of Business and Significant Accounting Policies	6 Months Ended
	Jun. 30, 2022
Accounting Policies [Abstract]
Nature of Business and Significant Accounting Policies	Note 1 – Nature of Business and Significant Accounting Policies Nature of Business WEED, Inc. (the “Company”), (formerly United Mines, Inc.) was incorporated under the laws of the State of Arizona on August 20, 1999 (“Inception Date”) as Plae, Inc. to engage in the exploration of gold and silver mining properties. On November 26, 2014, the Company was renamed from United Mines, Inc. to WEED, Inc. and was repurposed to pursue a business involving the purchase of land, and building Commercial Grade “Cultivation Centers” to consult, assist, manage & lease to Licensed Dispensary owners and organic grow operators on a contract basis, with a concentration on the legal and medical marijuana sector. The Company’s plan is to become a True “Seed-to-Sale” company providing infrastructure, financial solutions and real estate options in this new emerging market. The Company, under United Mines, was formerly in the process of acquiring mineral properties or claims located in the State of Arizona, USA. The name was previously changed on February 18, 2005 to King Mines, Inc. and then subsequently changed to United Mines, Inc. on March 30, 2005. The Company trades on the OTC Pink Sheets under the stock symbol: BUDZ. On April 20, 2017, the Company acquired Sangre AT, LLC, a Wyoming company doing business as Sangre AgroTech. (“Sangre”). Sangre is a plant genomic research and breeding company comprised of top-echelon scientists with extensive expertise in genomic sequencing, genetics-based breeding, plant tissue culture, and plant biochemistry, utilizing the most advanced sequencing and analytical technologies and proprietary bioinformatics data systems available. No work is being conducted now until further funds are available. On May 2, 2022, the Company acquired Hempirical Genetics, LLC, a Arizona company. The accompanying financial statements have been prepared in conformity with accounting principles generally accepted in the United States of America. These statements reflect all adjustments, consisting of normal recurring adjustments, which in the opinion of management are necessary for fair presentation of the information contained therein. The Company has a calendar year end for reporting purposes. Basis of Presentation: The accompanying condensed consolidated balance sheet at December 31, 2021, has been derived from audited consolidated financial statements and the unaudited condensed consolidated financial statements as of June 30, 2022 and 2021 ( the “financial statements”), have been prepared in accordance with accounting principles generally accepted in the United States of America (“GAAP”) for interim financial information and with the instructions to Form 10-Q and Article 8 of Regulation S-X. Accordingly, they do not include all of the information and footnotes required by GAAP for complete financial statements and should be read in conjunction with the audited consolidated financial statements and related footnotes included in our Registration Statement on Form S-1 for the year ended December 31, 2021 (the “2021 Annual Report”), filed with the Securities and Exchange Commission (the “SEC”). It is management’s opinion, however, that all material adjustments (consisting of normal recurring adjustments), have been made which are necessary for a fair financial statements presentation. The condensed consolidated financial statements include all material adjustments (consisting of normal recurring accruals) necessary to make the condensed consolidated financial statements not misleading as required by Regulation S-X, Rule 10-01. Principles of Consolidation The accompanying consolidated financial statements include the accounts of the following entities, all of which are under common control and ownership: Schedule of Entities under Common Control and Ownership State of Abbreviated Name of Entity Incorporation Relationship (1&3) Reference WEED, Inc. Nevada Parent WEED Sangre AT, LLC (2) Wyoming Subsidiary Sangre Hempirical Genetics, LLC Arizona Subsidiary Hempirical Generics (1) Sangre is a wholly-owned subsidiary of WEED, Inc. (2) Sangre AT, LLC is doing business as Sangre AgroTech. (3) Hempirical Genetics, LLC is a wholly-owned subsidiary of WEED, Inc. The consolidated financial statements herein contain the operations of the wholly-owned subsidiary listed above. All significant inter-company transactions have been eliminated in the preparation of these financial statements. The parent company, WEED and subsidiary, Sangre will be collectively referred to herein as the “Company”, or “WEED”. The Company’s headquarters are located in Tucson, Arizona and its operations are primarily within the United States, with minimal operations in Australia. These statements reflect all adjustments, consisting of normal recurring adjustments, which in the opinion of management are necessary for fair presentation of the information contained therein. Use of Estimates The preparation of financial statements in conformity with accounting principles generally accepted in the United States requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, and the disclosure of contingent assets and liabilities at the date of the financial statements, and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates. Fair Value of Financial Instruments Under FASB ASC 820-10-05, the Financial Accounting Standards Board establishes a framework for measuring fair value in generally accepted accounting principles and expands disclosures about fair value measurements. This Statement reaffirms that fair value is the relevant measurement attribute. The adoption of this standard did not have a material effect on the Company’s financial statements as reflected herein. The carrying amounts of cash, prepaid expenses and accrued expenses reported on the balance sheet are estimated by management to approximate fair value primarily due to the short term nature of the instruments. Impairment of Long-Lived Assets Long-lived assets held and used by the Company are reviewed for possible impairment whenever events or circumstances indicate the carrying amount of an asset may not be recoverable or is impaired. Recoverability is assessed using undiscounted cash flows based upon historical results and current projections of earnings before interest and taxes. Impairment is measured using discounted cash flows of future operating results based upon a rate that corresponds to the cost of capital. Impairments are recognized in operating results to the extent that carrying value exceeds discounted cash flows of future operations. Basic and Diluted Loss Per Share The basic net loss per common share is computed by dividing the net loss by the weighted average number of common shares outstanding. Diluted net loss per common share is computed by dividing the net loss adjusted on an “as if converted” basis, by the weighted average number of common shares outstanding plus potential dilutive securities. For the periods presented, potential dilutive securities had an anti-dilutive effect and were not included in the calculation of diluted net loss per common share. Stock-Based Compensation Under FASB ASC 718-10-30-2, all share-based payments to employees, including grants of employee stock options, to be recognized in the income statement based on their fair values. Pro forma disclosure is no longer an alternative. Revenue Recognition The Company is using the revenue recognition standard ASU 2014-09, “Revenue from Contracts with Customers (Topic 606)”, and using the cumulative effect (modified retrospective) approach. Modified retrospective adoption requires entities to apply the standard retrospectively to the most current period presented in the financial statements, requiring the cumulative effect of the retrospective application as an adjustment to the opening balance of retained earnings at the date of initial application. No cumulative-effect adjustment in retained earnings was recorded as the Company’s has no historical revenue. The impact of the adoption of the new standard was not material to the Company’s consolidated financial statements. The Company did not earn revenue during the periods ended June 30, 2022 and 2021. When the Company earns revenue, it will be recognized in accordance with FASB ASC 606 – Revenue from Contracts with Customers. The primary change under the new guidance is the requirement to report the allowance for uncollectible accounts as a reduction in net revenue as opposed to bad debt expense, a component of operating expenses. The adoption of this guidance did not have an impact on our condensed consolidated financial statements, other than additional financial statement disclosures. The guidance requires increased disclosures, including qualitative and quantitative disclosures about the nature, amount, timing and uncertainty of revenue and cash flows arising from contracts with customers. The Company operates as one reportable segment. Sales on fixed price contracts are recorded when services are earned, the earnings process is complete or substantially complete, and the revenue is measurable and collectability is reasonably assured. Provisions for discounts and rebates to customers, estimated returns and allowances, and other adjustments are provided for in the same period the related sales are recorded. The Company will defer any revenue from sales in which payment has been received, but the earnings process has not occurred. Sales have not yet commenced. Advertising and Promotion All costs associated with advertising and promoting products are expensed as incurred. These expenses were $ 9,751 500 Foreign Currency Transactions Expenses are translated at the exchange rates in effect at the date of the transaction. Foreign currency denominated payables are translated at the rates of exchange at the balance sheet date. The resulting transaction gains and losses are recorded in the statement of income in the period incurred. Assets and liabilities of those operations are translated at exchange rates in effect at the balance sheet date. Income and expenses are translated using the exchange rates on the transaction date for the reporting period. Translation adjustments, if any, are reported as a separate component of accumulated other comprehensive income. Transaction gain (loss) on foreign currency exchange rate was $ 1,553 ($487)

Going Concern

Going Concern	6 Months Ended
	Jun. 30, 2022
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Going Concern	Note 2 – Going Concern As shown in the accompanying financial statements, the Company has no revenues, incurred net losses from operations resulting in an accumulated deficit of $ 83,197,575 631,881 The financial statements do not include any adjustments that might result from the outcome of any uncertainty as to the Company’s ability to continue as a going concern. The financial statements also do not include any adjustments relating to the recoverability and classification of recorded asset amounts or amounts and classifications of liabilities that might be necessary should the Company be unable to continue as a going concern.

Related Party

Related Party	6 Months Ended
	Jun. 30, 2022
Related Party Transactions [Abstract]
Related Party	Note 3 – Related Party Notes Payable From time to time, the Company has received short term loans from officers and directors as disclosed in Note 8 below. The Company has a total of $ 897,661 596,401 30,500 8,000 7,000 18,000 300,000 4,000 500,000 Services Nicole M. Breen receives $1,500 a week in cash compensation for her services rendered to the Company. Glenn E. Martin receives $8,000 a month in cash compensation for his services rendered to the Company. Deposits Glenn E. Martin made the deposit of $50,000 on the Thorne Ranch property under his name. There is an agreement between Glenn E, Martin and the Company that if the property closes, Glenn E. Martin will transfer the title and all rights to the Company. The deposit was returned in June 2021. Accrued Compensation A total of $ 423,250 312,250

Fair Value of Financial Instrum

Fair Value of Financial Instruments	6 Months Ended
	Jun. 30, 2022
Fair Value Disclosures [Abstract]
Fair Value of Financial Instruments	Note 4 – Fair Value of Financial Instruments Under FASB ASC 820-10-5, fair value is defined as the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date (an exit price). The standard outlines a valuation framework and creates a fair value hierarchy in order to increase the consistency and comparability of fair value measurements and the related disclosures. Under GAAP, certain assets and liabilities must be measured at fair value, and FASB ASC 820-10-50 details the disclosures that are required for items measured at fair value. The Company has certain financial instruments that must be measured under the new fair value standard. The Company’s financial assets and liabilities are measured using inputs from the three levels of the fair value hierarchy. The three levels are as follows: Level 1 - Inputs are unadjusted quoted prices in active markets for identical assets or liabilities that the Company has the ability to access at the measurement date. Level 2 - Inputs include quoted prices for similar assets and liabilities in active markets, quoted prices for identical or similar assets or liabilities in markets that are not active, inputs other than quoted prices that are observable for the asset or liability (e.g., interest rates, yield curves, etc.), and inputs that are derived principally from or corroborated by observable market data by correlation or other means (market corroborated inputs). Level 3 - Unobservable inputs that reflect our assumptions about the assumptions that market participants would use in pricing the asset or liability. The following schedule summarizes the valuation of financial instruments at fair value on a recurring basis in the balance sheets as of June 30, 2022 and December 31, 2021, respectively: Schedule of Assets and Liabilities measured at Fair value, Recurring Fair Value Measurements at December 31, 2021 Level 1 Level 2 Level 3 Assets Cash $ 19,654 $ - $ - Intangible assets, net $ - $ 40,576 $ - Total assets $ 19,654 $ 40,576 $ - Liabilities Notes payable, related parties $ 596,401 Notes payable $ - $ 65,607 $ - Total liabilities $ - $ 662,008 $ - Total $ 19,654 $ 621,432 $ - Fair Value Measurements at June 30, 2022 Level 1 Level 2 Level 3 Assets Cash $ 821,094 $ - $ - Intangible assets, net $ - $ 519,616 $ - Total assets $ 821,094 $ 519,616 $ - Liabilities Notes payable, related parties $ 897,661 Notes payable $ - $ - $ - Total liabilities $ - $ 897,661 $ - Total $ 821,094 $ 378,045 $ - The fair values of our related party debts are deemed to approximate book value and are considered Level 2 inputs as defined by ASC Topic 820-10-35. There were no transfers of financial assets or liabilities between Level 1, Level 2 and Level 3 inputs for the six months ended June 30, 2022 and the year ended December 31, 2021.

Investment in Land and Property

Investment in Land and Property	6 Months Ended
	Jun. 30, 2022
Real Estate [Abstract]
Investment in Land and Property	Note 5 – Investment in Land and Property On June 25, 2019, the Company received $60,000 from Lex Seabre in exchange for 120,000 shares of common stock of the Company. The $60,000 was paid as a deposit for the Sugar Hill golf course property auction. On June 28, 2019, the Company received a loan of $12,000 from Nicole Breen. The $12,000 was paid as a deposit for the Sugar Hill golf course property auction. On September 25, 2019, the Company received $20,000 from Lex Seabre in exchange for 100,000 shares of common stock of the Company. The $20,000 was paid as a deposit for the additional 60-day extension for the Sugar Hill golf course property purchase. As of December 31, 2020, a total of $212,000 has been paid as a deposit for the Sugar Hill golf course property purchase. As of September 31, 2021, a total of $252,000 has been paid as a deposit for the Sugar Hill golf course property purchase. The Company entered into Memorandum of Sale agreement for the Sugar Hill property with M&T Bank and the Referee to make payment of $10,000 per month commencing on February 1, 2020 and continuing on the 1 st On November 11, 2021, the Company paid $245,000 to purchase the Sugar Hill golf course property. The total purchase price was $477,000.

Property and Equipment

Property and Equipment	6 Months Ended
	Jun. 30, 2022
Property, Plant and Equipment [Abstract]
Property and Equipment	Note 6 – Property and Equipment Property and equipment consist of the following at June 30, 2022 and December 31, 2021, respectively: Schedule of Property and Equipment June 30, December 31, 2022 2021 Property improvements $ 0 $ 5,000 Automobiles 0 0 Office equipment 8,667 8,667 Furniture & Fixtures 5,479 5,479 Lab equipment 153,569 65,769 Construction in progress 0 0 Land 372,069 383,027 Property 1,109,931 1,977,973 Property and equipment, gross 1,649,715 2,445,915 Less accumulated depreciation (367,175 ) (569,184 ) Property and equipment, net $ 1,282,540 $ 1,876,731 On May 12, 2022, the Company sold the La Veta property for $1,333,300 and $ 639,773 Depreciation expense totaled $ 62,354 59,877

Intangible Assets

Intangible Assets	6 Months Ended
	Jun. 30, 2022
Goodwill and Intangible Assets Disclosure [Abstract]
Intangible Assets	Note 7 – Intangible Assets Goodwill Goodwill represents the excess of the cost of a company acquired over the fair value of its net assets at the date of acquisition. Goodwill is assigned to specific reporting units and is reviewed for possible impairment at least annually or more frequently upon the occurrence of an event or when circumstances indicate that a reporting unit’s carrying amount is greater than its fair value. On May 02, 2022, WEED acquired the entire interests in Hempirical Genetics, LLC. which resulted in $ 480,200 Intangibles In accordance with FASB ASC 350, “Intangibles-Goodwill and Other”, the Company evaluates the recoverability of identifiable intangible assets whenever events or changes in circumstances indicate that an intangible asset’s carrying amount may not be recoverable. The impairment loss would be calculated as the amount by which the carrying value of the asset exceeds its fair value. The US and Europe trademarks were acquired for $40,000 and $50,000, respectively, for the year ended December 31, 2018. Trademarks are initially measured based on their fair value and amortized by 10 and 25 years. Acquisition intangible assets arising out of the acquisition of Hempirical Genetics, LLC. that should, in accordance with GAAP, be classified as intangibles, include goodwill. On June 30, 2022, Intangibles consists of the following: Schedule of Intangible Assets June 30, 2022 December 31, 2021 Trademark 50,000 50,000 Less: Accumulated amortization (10,584) (9,424) Total other intangibles, Net 39,416 40,576 Goodwill, Net 480,200 0 Total Intangibles, Net 519,616 40,576 Amortization expense totaled $ 1,441 1,083

Note 8 _ Notes Payable, Related

Note 8 – Notes Payable, Related Parties	6 Months Ended
	Jun. 30, 2022
Note 8 Notes Payable Related Parties
Note 8 – Notes Payable, Related Parties	Note 8 – Notes Payable, Related Parties Notes payable, related parties consist of the following at June 30, 2022 and December 31, 2021, respectively: Schedule of Notes Payable, Related Party June 30, 2022 December 31, 2021 On April 12, 2010, the Company received an unsecured, non-interest-bearing loan in the amount of $2,000, due on demand from Robert Leitzman. Interest is being imputed at the Company’s estimated borrowing rate, or 10% per annum. The largest aggregate amount outstanding was $2,000 during the periods ended December 31, 2019 and December 31, 2018. Mr. Leitzman owns less than 1% of the Company’s common stock, however, the Mr. Leitzman is deemed to be a related party given the non-interest-bearing nature of the loan and the materiality of the debt at the time of origination. $ 2,000 2,000 Over various dates in 2011 and 2012, the Company received unsecured loans in the aggregate amount of $10,000, due on demand, bearing interest at 10%, from Sandra Orman. The largest aggregate amount outstanding was $10,000 during the periods ended December 31, 2019 and December 31, 2018. Mrs. Orman owns less than 1% of the Company’s common stock, however, Mrs. Orman is deemed to be a related party given the nature of the loan and the materiality of the debt at the time of origination. $ 10,000 10,000 Over various dates from April 2019 to March 2022, the company received a net amount of $356,700 of advances, bearing interest at 5%, from Nicole Breen. On October 28, 2019, the company’s vehicles valued at $93,000 were used as a repayment. $ 168,109 On November 2, 2021, the company received an unsecured loan in the amount of $300,000, bearing interest at 5%, from Glenn Martin. The loan was paid off on March 1, 2022. 309,700 On March 1, 2022, the company received an unsecured loan in the amount of $500,000, bearing interest at 9.25%, from Glenn Martin. $ 500,000 On May 2, 2022, the company acquired Hempirical Genetics, LLC with a note payable to the executive officer Jeffrey Miller $ 240,000 300,000 Notes payable, related parties $ 920,109 $ 621,700 Less: Loan fee, net of amortization 22,448 25,299 Notes payable, related parties $ 897,661 596,401 The Company recorded interest expense in the amount of $48,821 and $26,800 for the six months ended June 30, 2022 and 2021, respectively, including imputed interest expense in the amount of $18,235 and $8,017 during such periods related to notes payable, related parties.

Notes Payable

Notes Payable	6 Months Ended
	Jun. 30, 2022
Debt Disclosure [Abstract]
Notes Payable	Note 9 – Notes Payable Note payable consist of the following at June 30, 2022 and December 31, 2021, respectively: Schedule of Notes Payable June 30, 2022 December 31, 2021 On August 5, 2019, the Company entered into a promissory note, whereby the Company promises to pay Snell & Wilmer L.L.P the principal amount of $250,000, bearing interest at 2.5% per annum. The note is to be paid in consecutive monthly installments in the amount of $25,000, including accrued interest commencing on August 30, 2019, until the final balloon payment is paid on January 30, 2020. The note is in default. The promissory note is secured by the Deed of Trust, Assignment of Leases and Rents, Security Agreement and Fixture Filing with respect to the real property owned by Sangre located on 1390 Mountain Valley Road, La Veta, Colorado 81055. As of March 2022, $337,664 has been paid to Snell & Wilmer. $ 0 54,169 On various dates, the Company received advances from consultant, Patrick Brodnik, bearing 5% interest. $ 0 11,438 $ 0 $ 65,607 The Company recognized interest expense of $ 697 1,338

Commitments and Contingencies

Commitments and Contingencies	6 Months Ended
	Jun. 30, 2022
Commitments and Contingencies Disclosure [Abstract]
Commitments and Contingencies	Note 10 – Commitments and Contingencies On January 19, 2018, the Company was sued in the United States District Court for the District of Arizona ( William Martin v. WEED, Inc.) Travis Nelson v. Sangre AgroTech, LLC, et al. (Huerfeno County Colorado District Court, Case No. 2018CV30003, filed on February 5, 2018). Mr. Travis Nelson, formerly a member of the subsidiary Sangre AgroTech, LLC, filed this action alleging wrongful discharge in retaliation for whistleblower activity purportedly related to insider trading, fraud and unlawful interstate transportation of plant genetics. After a motion to dismiss was granted in part, Mr. Nelson filed a second amended complaint asserting revised claims for breach of fiduciary duty, wrongful discharge, and violation of the Colorado organized crime control act. Mr. Nelson has alleged lost wages in the amount of $600,000, unspecified losses related to whistleblower allegations, plus costs and attorneys’ fees. In his initial disclosures, Mr. Nelson alleges damages of $10,000,000. On January 31, 2019, Mr. Nelson submitted an offer of judgement in the amount of $100,000. That offer was rejected by the Corporation. Court-ordered mediation was conducted on April 24, 2019, but the matter was not resolved. By order dated February 4, 2020, the court scheduled trial for October 5, 2020. The Corporation denies liability as to all claims. Inasmuch as an unfavorable outcome is neither probable nor remote within the meaning of the ABA Statement of Policy referred to in the last paragraph of this letter, we decline to express an opinion concerning the likely outcome of this matter or the liability of the Corporation, if any, associated therewith. Operating Leases We account for our lease under ASC 842. Under this guidance, arrangements meeting the definition of a lease are classified as operating and are recorded on the consolidated balance sheet as both a right of use asset and lease liability, calculated by discounting fixed lease payments over the lease term at the rate implicit in the lease. Lease liabilities are increased by interest and reduced by payments each period, and the right of use asset is amortized over the lease term. The rate implicit in lease is not readily determinable, and we therefore use incremental borrowing rate to determine the present value of the lease payments. The incremental borrowing rate used to determine the initial value of right-of-use (“ROU”) assets and lease liabilities during the period ended June 30, 2022, was 5.0%. In May, 2022, we entered into a lease agreement of a hemp drying facility in Huachuca City, Arizona for $1,200 per month. The lease term began May 2, 2022 and ends May 2, 2026. As of June 30, 2022, we had lease liability of $ 50,139 50,139 Legal Proceedings The Company may be subject to legal proceedings and claims arising from contracts or other matters from time to time in the ordinary course of business. Management is not aware of any pending or threatened litigation where the ultimate disposition or resolution could have a material adverse effect on its financial position, results of operations or liquidity.

Business Combination

Business Combination	6 Months Ended
	Jun. 30, 2022
Business Combination and Asset Acquisition [Abstract]
Business Combination	Note 11 – Business Combination On May 02, 2022, Weed acquired 100% of the interest in Hempirical Genetics LLC. The consideration was paid in a total of 2,000,000 650,000 Pro forma information related to the operations of Hempirical are not disclosed as such operations were insignificant for the historical periods. The following summarized the estimate fair value of the acquired assets as of the date of the transaction: Schedule of Proforma Estimate Fair Value of Assets Inventory $ 82,000 Equipment 87,800 Total assets acquired 169,800 Goodwill 480,200 Total Consideration $ 650,000

Stockholders_ Equity

Stockholders’ Equity	6 Months Ended
	Jun. 30, 2022
Equity [Abstract]
Stockholders’ Equity	Note 12 – Stockholders’ Equity Preferred Stock On December 5, 2014, the Company amended the Articles of Incorporation, pursuant to which 20,000,000 0.001 Common Stock On December 5, 2014, the Company amended the Articles of Incorporation, and increased the authorized shares to 200,000,000 0.001 2022 Common Stock Activity Common Stock Sales (2022) During the period ended June 30, 2022, the Company issued 300,000 40,000 Common Stock Issued for Services (2022) During the six months ended June 30, 2022, the Company agreed to issue an aggregate of 2,080,000 457,800 Common Stock Issued for Acquisition (2022) During the period ended June 30, 2022, the Company issued 1,000,000 Common Stock Cancellations No common stocks were cancelled during the quarter ended June 30, 2022. 2021 Common Stock Activity Common Stock Sales (2021) During the year ended December 31, 2021, the Company issued 2,200,000 560,000 Common Stock Issued for Services (2021) During the year ended December 31, 2021, the Company agreed to issue an aggregate of 3,650,000 2,002,850 Common Stock Cancellations No common stocks were cancelled during the year ended December 31, 2021.

Common Stock Warrants and Optio

Common Stock Warrants and Options	6 Months Ended
	Jun. 30, 2022
Common Stock Warrants And Options
Common Stock Warrants and Options	Note 13 – Common Stock Warrants and Options Common Stock Warrants Granted (2022) No common stock warrants were granted during the six months ended June 30, 2022 and December 31, 2021. Warrants Exercised (2022) No warrants were exercised during the six months ended June 30, 2022. 2021 Common Stock Warrant Activity Common Stock Warrants Granted (2021) No common stock warrants were granted during the year ended December 31, 2021. Common Stock Warrants Expired (2020) A total of 200,000 Warrants Exercised (2020) No warrants were exercised during the year ended December 31, 2020. Common Stock Options (2019) A summary of the Company’s stock option activity and related information is as follows: For the Six Months Ended June 30, 2021 Number of Average Shares Price Outstanding at the beginning of period $ 6,000,000 $ 10.55 Granted - - Exercised/Expired/Cancelled - - Outstanding at the end of period 6,000,000 $ 10.55 Exercisable at the end of period 6,000,000 $ 10.55 For the Six Months Ended June 30, 2022 Number of Average Shares Price Outstanding at the beginning of period $ 6,000,000 $ 10.55 Granted - - Exercised/Expired/Cancelled - - Outstanding at the end of period 6,000,000 $ 10.55 Exercisable at the end of period 6,000,000 $ 10.55

Income Tax

Income Tax	6 Months Ended
	Jun. 30, 2022
Income Tax Disclosure [Abstract]
Income Tax	Note 14 – Income Tax The Company accounts for income taxes under FASB ASC 740-10, which requires use of the liability method. FASB ASC 740-10-25 provided that deferred tax assets and liabilities, are recorded based on the differences between the tax bases of assets and liabilities and their carrying amounts for financial reporting purposes, referred to as temporary differences. For the six months ended June 30, 2022 and the year ended December 31, 2021, the Company incurred a net operating loss and, accordingly, no provision for income taxes has been recorded. In addition, no benefit for income taxes has been recorded due to the uncertainty of the realization of any tax assets. At June 30, 2022 and December 31, 2021, the Company had approximately $ 364,674 2,683,947 The components of the Company’s deferred tax asset are as follows: Schedule of Deferred Tax Assets June 30, 2022 Deferred tax assets: Net operating loss carry forward as of 12/31/2021 12,817,540 Estimate Tax Loss June 30, 2022 364,674 Add back shares for services (457,800 ) NOL Carry Forward Cumulative as of 6/30/2022 12,724,414 Statutory Tax Rate 21 % Deferred Tax Asset 2,672,127 Valuation (2,672,127 ) Net Deferred Tax Asset 0 Based on the available objective evidence, including the Company’s history of losses, management believes it is more likely than not that the net deferred tax assets will not be fully realizable. Accordingly, the Company provided for a full valuation allowance against its net deferred tax assets at June 30, 2022 and December 31, 2021, respectively.

Subsequent Events

Subsequent Events	6 Months Ended
	Jun. 30, 2022
Subsequent Events [Abstract]
Subsequent Events	Note 15 – Subsequent Events We have evaluated subsequent events through the filing date of this Form 10-Q and determined that few subsequent events have occurred that would require recognition in the consolidated financial statements or disclosures in the notes thereto.

Nature of Business and Signif_2

Nature of Business and Significant Accounting Policies (Policies)	6 Months Ended
	Jun. 30, 2022
Accounting Policies [Abstract]
Nature of Business	Nature of Business WEED, Inc. (the “Company”), (formerly United Mines, Inc.) was incorporated under the laws of the State of Arizona on August 20, 1999 (“Inception Date”) as Plae, Inc. to engage in the exploration of gold and silver mining properties. On November 26, 2014, the Company was renamed from United Mines, Inc. to WEED, Inc. and was repurposed to pursue a business involving the purchase of land, and building Commercial Grade “Cultivation Centers” to consult, assist, manage & lease to Licensed Dispensary owners and organic grow operators on a contract basis, with a concentration on the legal and medical marijuana sector. The Company’s plan is to become a True “Seed-to-Sale” company providing infrastructure, financial solutions and real estate options in this new emerging market. The Company, under United Mines, was formerly in the process of acquiring mineral properties or claims located in the State of Arizona, USA. The name was previously changed on February 18, 2005 to King Mines, Inc. and then subsequently changed to United Mines, Inc. on March 30, 2005. The Company trades on the OTC Pink Sheets under the stock symbol: BUDZ. On April 20, 2017, the Company acquired Sangre AT, LLC, a Wyoming company doing business as Sangre AgroTech. (“Sangre”). Sangre is a plant genomic research and breeding company comprised of top-echelon scientists with extensive expertise in genomic sequencing, genetics-based breeding, plant tissue culture, and plant biochemistry, utilizing the most advanced sequencing and analytical technologies and proprietary bioinformatics data systems available. No work is being conducted now until further funds are available. On May 2, 2022, the Company acquired Hempirical Genetics, LLC, a Arizona company. The accompanying financial statements have been prepared in conformity with accounting principles generally accepted in the United States of America. These statements reflect all adjustments, consisting of normal recurring adjustments, which in the opinion of management are necessary for fair presentation of the information contained therein. The Company has a calendar year end for reporting purposes.
Basis of Presentation:	Basis of Presentation: The accompanying condensed consolidated balance sheet at December 31, 2021, has been derived from audited consolidated financial statements and the unaudited condensed consolidated financial statements as of June 30, 2022 and 2021 ( the “financial statements”), have been prepared in accordance with accounting principles generally accepted in the United States of America (“GAAP”) for interim financial information and with the instructions to Form 10-Q and Article 8 of Regulation S-X. Accordingly, they do not include all of the information and footnotes required by GAAP for complete financial statements and should be read in conjunction with the audited consolidated financial statements and related footnotes included in our Registration Statement on Form S-1 for the year ended December 31, 2021 (the “2021 Annual Report”), filed with the Securities and Exchange Commission (the “SEC”). It is management’s opinion, however, that all material adjustments (consisting of normal recurring adjustments), have been made which are necessary for a fair financial statements presentation. The condensed consolidated financial statements include all material adjustments (consisting of normal recurring accruals) necessary to make the condensed consolidated financial statements not misleading as required by Regulation S-X, Rule 10-01.
Principles of Consolidation	Principles of Consolidation The accompanying consolidated financial statements include the accounts of the following entities, all of which are under common control and ownership: Schedule of Entities under Common Control and Ownership State of Abbreviated Name of Entity Incorporation Relationship (1&3) Reference WEED, Inc. Nevada Parent WEED Sangre AT, LLC (2) Wyoming Subsidiary Sangre Hempirical Genetics, LLC Arizona Subsidiary Hempirical Generics (1) Sangre is a wholly-owned subsidiary of WEED, Inc. (2) Sangre AT, LLC is doing business as Sangre AgroTech. (3) Hempirical Genetics, LLC is a wholly-owned subsidiary of WEED, Inc. The consolidated financial statements herein contain the operations of the wholly-owned subsidiary listed above. All significant inter-company transactions have been eliminated in the preparation of these financial statements. The parent company, WEED and subsidiary, Sangre will be collectively referred to herein as the “Company”, or “WEED”. The Company’s headquarters are located in Tucson, Arizona and its operations are primarily within the United States, with minimal operations in Australia. These statements reflect all adjustments, consisting of normal recurring adjustments, which in the opinion of management are necessary for fair presentation of the information contained therein.
Use of Estimates	Use of Estimates The preparation of financial statements in conformity with accounting principles generally accepted in the United States requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, and the disclosure of contingent assets and liabilities at the date of the financial statements, and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates.
Fair Value of Financial Instruments	Fair Value of Financial Instruments Under FASB ASC 820-10-05, the Financial Accounting Standards Board establishes a framework for measuring fair value in generally accepted accounting principles and expands disclosures about fair value measurements. This Statement reaffirms that fair value is the relevant measurement attribute. The adoption of this standard did not have a material effect on the Company’s financial statements as reflected herein. The carrying amounts of cash, prepaid expenses and accrued expenses reported on the balance sheet are estimated by management to approximate fair value primarily due to the short term nature of the instruments.
Impairment of Long-Lived Assets	Impairment of Long-Lived Assets Long-lived assets held and used by the Company are reviewed for possible impairment whenever events or circumstances indicate the carrying amount of an asset may not be recoverable or is impaired. Recoverability is assessed using undiscounted cash flows based upon historical results and current projections of earnings before interest and taxes. Impairment is measured using discounted cash flows of future operating results based upon a rate that corresponds to the cost of capital. Impairments are recognized in operating results to the extent that carrying value exceeds discounted cash flows of future operations.
Basic and Diluted Loss Per Share	Basic and Diluted Loss Per Share The basic net loss per common share is computed by dividing the net loss by the weighted average number of common shares outstanding. Diluted net loss per common share is computed by dividing the net loss adjusted on an “as if converted” basis, by the weighted average number of common shares outstanding plus potential dilutive securities. For the periods presented, potential dilutive securities had an anti-dilutive effect and were not included in the calculation of diluted net loss per common share.
Stock-Based Compensation	Stock-Based Compensation Under FASB ASC 718-10-30-2, all share-based payments to employees, including grants of employee stock options, to be recognized in the income statement based on their fair values. Pro forma disclosure is no longer an alternative.
Revenue Recognition	Revenue Recognition The Company is using the revenue recognition standard ASU 2014-09, “Revenue from Contracts with Customers (Topic 606)”, and using the cumulative effect (modified retrospective) approach. Modified retrospective adoption requires entities to apply the standard retrospectively to the most current period presented in the financial statements, requiring the cumulative effect of the retrospective application as an adjustment to the opening balance of retained earnings at the date of initial application. No cumulative-effect adjustment in retained earnings was recorded as the Company’s has no historical revenue. The impact of the adoption of the new standard was not material to the Company’s consolidated financial statements. The Company did not earn revenue during the periods ended June 30, 2022 and 2021. When the Company earns revenue, it will be recognized in accordance with FASB ASC 606 – Revenue from Contracts with Customers. The primary change under the new guidance is the requirement to report the allowance for uncollectible accounts as a reduction in net revenue as opposed to bad debt expense, a component of operating expenses. The adoption of this guidance did not have an impact on our condensed consolidated financial statements, other than additional financial statement disclosures. The guidance requires increased disclosures, including qualitative and quantitative disclosures about the nature, amount, timing and uncertainty of revenue and cash flows arising from contracts with customers. The Company operates as one reportable segment. Sales on fixed price contracts are recorded when services are earned, the earnings process is complete or substantially complete, and the revenue is measurable and collectability is reasonably assured. Provisions for discounts and rebates to customers, estimated returns and allowances, and other adjustments are provided for in the same period the related sales are recorded. The Company will defer any revenue from sales in which payment has been received, but the earnings process has not occurred. Sales have not yet commenced.
Advertising and Promotion	Advertising and Promotion All costs associated with advertising and promoting products are expensed as incurred. These expenses were $ 9,751 500
Foreign Currency Transactions	Foreign Currency Transactions Expenses are translated at the exchange rates in effect at the date of the transaction. Foreign currency denominated payables are translated at the rates of exchange at the balance sheet date. The resulting transaction gains and losses are recorded in the statement of income in the period incurred. Assets and liabilities of those operations are translated at exchange rates in effect at the balance sheet date. Income and expenses are translated using the exchange rates on the transaction date for the reporting period. Translation adjustments, if any, are reported as a separate component of accumulated other comprehensive income. Transaction gain (loss) on foreign currency exchange rate was $ 1,553 ($487)

Nature of Business and Signif_3

Nature of Business and Significant Accounting Policies (Tables)	6 Months Ended
	Jun. 30, 2022
Accounting Policies [Abstract]
Schedule of Entities under Common Control and Ownership	The accompanying consolidated financial statements include the accounts of the following entities, all of which are under common control and ownership: Schedule of Entities under Common Control and Ownership
Nature of Business and Significant Accounting Policies	State of Abbreviated Name of Entity Incorporation Relationship (1&3) Reference WEED, Inc. Nevada Parent WEED Sangre AT, LLC (2) Wyoming Subsidiary Sangre Hempirical Genetics, LLC Arizona Subsidiary Hempirical Generics

Fair Value of Financial Instr_2

Fair Value of Financial Instruments (Tables)	6 Months Ended
	Jun. 30, 2022
Fair Value Disclosures [Abstract]
Schedule of Assets and Liabilities measured at Fair value, Recurring	The following schedule summarizes the valuation of financial instruments at fair value on a recurring basis in the balance sheets as of June 30, 2022 and December 31, 2021, respectively: Schedule of Assets and Liabilities measured at Fair value, Recurring Fair Value Measurements at December 31, 2021 Level 1 Level 2 Level 3 Assets Cash $ 19,654 $ - $ - Intangible assets, net $ - $ 40,576 $ - Total assets $ 19,654 $ 40,576 $ - Liabilities Notes payable, related parties $ 596,401 Notes payable $ - $ 65,607 $ - Total liabilities $ - $ 662,008 $ - Total $ 19,654 $ 621,432 $ - Fair Value Measurements at June 30, 2022 Level 1 Level 2 Level 3 Assets Cash $ 821,094 $ - $ - Intangible assets, net $ - $ 519,616 $ - Total assets $ 821,094 $ 519,616 $ - Liabilities Notes payable, related parties $ 897,661 Notes payable $ - $ - $ - Total liabilities $ - $ 897,661 $ - Total $ 821,094 $ 378,045 $ -
[custom:DisclosureFairValueOfFinancialInstrumentsDetailsAbstract]	Level 1 Level 2 Level 3 Assets Cash $ 19,654 $ - $ - Intangible assets, net $ - $ 40,576 $ - Total assets $ 19,654 $ 40,576 $ - Liabilities Notes payable, related parties $ 596,401 Notes payable $ - $ 65,607 $ - Total liabilities $ - $ 662,008 $ - Total $ 19,654 $ 621,432 $ - Fair Value Measurements at June 30, 2022 Level 1 Level 2 Level 3 Assets Cash $ 821,094 $ - $ - Intangible assets, net $ - $ 519,616 $ - Total assets $ 821,094 $ 519,616 $ - Liabilities Notes payable, related parties $ 897,661 Notes payable $ - $ - $ - Total liabilities $ - $ 897,661 $ - Total $ 821,094 $ 378,045 $ -

Property and Equipment (Tables)

Property and Equipment (Tables)	6 Months Ended
	Jun. 30, 2022
Property, Plant and Equipment [Abstract]
Schedule of Property and Equipment	Property and equipment consist of the following at June 30, 2022 and December 31, 2021, respectively: Schedule of Property and Equipment
Property and Equipment	June 30, December 31, 2022 2021 Property improvements $ 0 $ 5,000 Automobiles 0 0 Office equipment 8,667 8,667 Furniture & Fixtures 5,479 5,479 Lab equipment 153,569 65,769 Construction in progress 0 0 Land 372,069 383,027 Property 1,109,931 1,977,973 Property and equipment, gross 1,649,715 2,445,915 Less accumulated depreciation (367,175 ) (569,184 ) Property and equipment, net $ 1,282,540 $ 1,876,731

Intangible Assets (Tables)

Intangible Assets (Tables)	6 Months Ended
	Jun. 30, 2022
Goodwill and Intangible Assets Disclosure [Abstract]
Schedule of Intangible Assets	Schedule of Intangible Assets
Intangible Assets	June 30, 2022 December 31, 2021 Trademark 50,000 50,000 Less: Accumulated amortization (10,584) (9,424) Total other intangibles, Net 39,416 40,576 Goodwill, Net 480,200 0 Total Intangibles, Net 519,616 40,576

Note 8 _ Notes Payable, Relat_2

Note 8 – Notes Payable, Related Parties (Tables)	6 Months Ended
	Jun. 30, 2022
Note 8 Notes Payable Related Parties
Schedule of Notes Payable, Related Party	Notes payable, related parties consist of the following at June 30, 2022 and December 31, 2021, respectively: Schedule of Notes Payable, Related Party June 30, 2022 December 31, 2021 On April 12, 2010, the Company received an unsecured, non-interest-bearing loan in the amount of $2,000, due on demand from Robert Leitzman. Interest is being imputed at the Company’s estimated borrowing rate, or 10% per annum. The largest aggregate amount outstanding was $2,000 during the periods ended December 31, 2019 and December 31, 2018. Mr. Leitzman owns less than 1% of the Company’s common stock, however, the Mr. Leitzman is deemed to be a related party given the non-interest-bearing nature of the loan and the materiality of the debt at the time of origination. $ 2,000 2,000 Over various dates in 2011 and 2012, the Company received unsecured loans in the aggregate amount of $10,000, due on demand, bearing interest at 10%, from Sandra Orman. The largest aggregate amount outstanding was $10,000 during the periods ended December 31, 2019 and December 31, 2018. Mrs. Orman owns less than 1% of the Company’s common stock, however, Mrs. Orman is deemed to be a related party given the nature of the loan and the materiality of the debt at the time of origination. $ 10,000 10,000 Over various dates from April 2019 to March 2022, the company received a net amount of $356,700 of advances, bearing interest at 5%, from Nicole Breen. On October 28, 2019, the company’s vehicles valued at $93,000 were used as a repayment. $ 168,109 On November 2, 2021, the company received an unsecured loan in the amount of $300,000, bearing interest at 5%, from Glenn Martin. The loan was paid off on March 1, 2022. 309,700 On March 1, 2022, the company received an unsecured loan in the amount of $500,000, bearing interest at 9.25%, from Glenn Martin. $ 500,000 On May 2, 2022, the company acquired Hempirical Genetics, LLC with a note payable to the executive officer Jeffrey Miller $ 240,000 300,000 Notes payable, related parties $ 920,109 $ 621,700 Less: Loan fee, net of amortization 22,448 25,299 Notes payable, related parties $ 897,661 596,401

Notes Payable (Tables)

Notes Payable (Tables)	6 Months Ended
	Jun. 30, 2022
Debt Disclosure [Abstract]
Schedule of Notes Payable	Note payable consist of the following at June 30, 2022 and December 31, 2021, respectively: Schedule of Notes Payable June 30, 2022 December 31, 2021 On August 5, 2019, the Company entered into a promissory note, whereby the Company promises to pay Snell & Wilmer L.L.P the principal amount of $250,000, bearing interest at 2.5% per annum. The note is to be paid in consecutive monthly installments in the amount of $25,000, including accrued interest commencing on August 30, 2019, until the final balloon payment is paid on January 30, 2020. The note is in default. The promissory note is secured by the Deed of Trust, Assignment of Leases and Rents, Security Agreement and Fixture Filing with respect to the real property owned by Sangre located on 1390 Mountain Valley Road, La Veta, Colorado 81055. As of March 2022, $337,664 has been paid to Snell & Wilmer. $ 0 54,169 On various dates, the Company received advances from consultant, Patrick Brodnik, bearing 5% interest. $ 0 11,438 $ 0 $ 65,607

Business Combination (Tables)

Business Combination (Tables)	6 Months Ended
	Jun. 30, 2022
Business Combination and Asset Acquisition [Abstract]
Schedule of Proforma Estimate Fair Value of Assets	The following summarized the estimate fair value of the acquired assets as of the date of the transaction: Schedule of Proforma Estimate Fair Value of Assets
Business Combination	Inventory $ 82,000 Equipment 87,800 Total assets acquired 169,800 Goodwill 480,200 Total Consideration $ 650,000

Common Stock Warrants and Opt_2

Common Stock Warrants and Options (Tables)	6 Months Ended
	Jun. 30, 2022
Common Stock Warrants And Options
A summary of the Company’s stock option activity and related information is as follows:	A summary of the Company’s stock option activity and related information is as follows:
Common Stock Warrants and Options	For the Six Months Ended June 30, 2021 Number of Average Shares Price Outstanding at the beginning of period $ 6,000,000 $ 10.55 Granted - - Exercised/Expired/Cancelled - - Outstanding at the end of period 6,000,000 $ 10.55 Exercisable at the end of period 6,000,000 $ 10.55 For the Six Months Ended June 30, 2022 Number of Average Shares Price Outstanding at the beginning of period $ 6,000,000 $ 10.55 Granted - - Exercised/Expired/Cancelled - - Outstanding at the end of period 6,000,000 $ 10.55 Exercisable at the end of period 6,000,000 $ 10.55

Income Tax (Tables)

Income Tax (Tables)	6 Months Ended
	Jun. 30, 2022
Income Tax Disclosure [Abstract]
Schedule of Deferred Tax Assets	The components of the Company’s deferred tax asset are as follows: Schedule of Deferred Tax Assets
Income Tax	June 30, 2022 Deferred tax assets: Net operating loss carry forward as of 12/31/2021 12,817,540 Estimate Tax Loss June 30, 2022 364,674 Add back shares for services (457,800 ) NOL Carry Forward Cumulative as of 6/30/2022 12,724,414 Statutory Tax Rate 21 % Deferred Tax Asset 2,672,127 Valuation (2,672,127 ) Net Deferred Tax Asset 0

Nature of Business and Signif_4

Nature of Business and Significant Accounting Policies (Details)	6 Months Ended
	Jun. 30, 2022	[1],[2]
Weed Inc. [Member]
Parent Entity Legal Name	WEED, Inc.
Sangre A T L L C [Member]
Parent Entity Legal Name	Sangre AT, LLC	[3]
Hempirical Genetics L L C [Member]
Parent Entity Legal Name	Hempirical Genetics, LLC	[3]
[1]Hempirical Genetics, LLC is a wholly-owned subsidiary of WEED, Inc.[2]Sangre is a wholly-owned subsidiary of WEED, Inc.[3]Sangre AT, LLC is doing business as Sangre AgroTech.

Nature of Business and Signif_5

Nature of Business and Significant Accounting Policies (Details Narrative) - USD ($)	3 Months Ended		6 Months Ended
	Jun. 30, 2022	Jun. 30, 2021	Jun. 30, 2022	Jun. 30, 2021
Accounting Policies [Abstract]
Advertising Expense			$ 9,751	$ 500
Other Comprehensive Income (Loss), Net of Tax	$ 2,309	$ 75	$ 1,553	$ (487)

Going Concern (Details Narrativ

Going Concern (Details Narrative) - USD ($)	Jun. 30, 2022	Dec. 31, 2021
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Retained Earnings (Accumulated Deficit)	$ 83,197,575	$ 82,832,901
Working Capital Deficit	$ 631,881

Related Party (Details Narrativ

Related Party (Details Narrative) - USD ($)	3 Months Ended					6 Months Ended
	Mar. 31, 2022	Dec. 31, 2021	Sep. 30, 2021	Jun. 30, 2021	Mar. 31, 2021	Jun. 30, 2022	Jun. 30, 2021
Related Party Transaction [Line Items]
Notes Payable, Related Parties, Current		$ 596,401				$ 897,661
Proceeds from Related Party Debt
Accrued Bonuses, Current		365,750		$ 312,250		$ 423,250	$ 312,250
Nicole Breen [Member]
Related Party Transaction [Line Items]
Proceeds from Related Party Debt	$ 4,000	18,000	$ 7,000	$ 8,000	$ 30,500
Glenn Martin [Member]
Related Party Transaction [Line Items]
Proceeds from Related Party Debt	$ 500,000	$ 300,000

Fair Value of Financial Instr_3

Fair Value of Financial Instruments (Details) - USD ($)	Jun. 30, 2022	Dec. 31, 2021	Jun. 30, 2021	Dec. 31, 2020
Assets
Cash	$ 821,094	$ 19,654	$ 38,602	$ 12,629
Intangible assets, net	519,616	40,576
Total assets	2,774,479	1,959,225
Liabilities
Notes payable, related parties	897,661	596,401
Notes payable	0	65,607
Total liabilities	1,554,065	1,341,725
Fair Value, Recurring [Member] | Fair Value, Inputs, Level 1 [Member]
Assets
Cash	821,094	19,654
Intangible assets, net
Total assets	821,094	19,654
Liabilities
Notes payable
Total liabilities
Total	821,094	19,654
Fair Value, Recurring [Member] | Fair Value, Inputs, Level 2 [Member]
Assets
Cash
Intangible assets, net	519,616	40,576
Total assets	519,616	40,576
Liabilities
Notes payable, related parties	897,661	596,401
Notes payable		65,607
Total liabilities	897,661	662,008
Total	378,045	621,432
Fair Value, Recurring [Member] | Fair Value, Inputs, Level 3 [Member]
Assets
Cash
Intangible assets, net
Total assets
Liabilities
Notes payable
Total liabilities
Total

Property and Equipment (Details

Property and Equipment (Details) - USD ($)	Jun. 30, 2022	Dec. 31, 2021
Property, Plant and Equipment [Line Items]
Property and equipment, gross	$ 1,649,715	$ 2,445,915
Less accumulated depreciation	(367,175)	(569,184)
Property and equipment, net	1,282,540	1,876,731
Building Improvements [Member]
Property, Plant and Equipment [Line Items]
Property and equipment, gross	0	5,000
Automobiles [Member]
Property, Plant and Equipment [Line Items]
Property and equipment, gross	0	0
Office Equipment [Member]
Property, Plant and Equipment [Line Items]
Property and equipment, gross	8,667	8,667
Furniture and Fixtures [Member]
Property, Plant and Equipment [Line Items]
Property and equipment, gross	5,479	5,479
Equipment [Member]
Property, Plant and Equipment [Line Items]
Property and equipment, gross	153,569	65,769
Construction in Progress [Member]
Property, Plant and Equipment [Line Items]
Property and equipment, gross	0	0
Land [Member]
Property, Plant and Equipment [Line Items]
Property and equipment, gross	372,069	383,027
Land and Building [Member]
Property, Plant and Equipment [Line Items]
Property and equipment, gross	$ 1,109,931	$ 1,977,973

Property and Equipment (Detai_2

Property and Equipment (Details Narrative) - USD ($)		3 Months Ended		6 Months Ended
	May 12, 2022	Jun. 30, 2022	Jun. 30, 2021	Jun. 30, 2022	Jun. 30, 2021
Property, Plant and Equipment [Abstract]
Gain (Loss) on Disposition of Property Plant Equipment	$ 639,773	$ 639,773		$ 639,773
Depreciation				$ 62,354	$ 59,877

Intangible Assets (Details)

Intangible Assets (Details) - USD ($)	Jun. 30, 2022	Dec. 31, 2021
Goodwill and Intangible Assets Disclosure [Abstract]
Trademark	$ 50,000	$ 50,000
Less: Accumulated amortization	(10,584)	(9,424)
Total other intangibles, Net	39,416	40,576
Goodwill, Net	480,200	0
Total Intangibles, Net	$ 519,616	$ 40,576

Intangible Assets (Details Narr

Intangible Assets (Details Narrative) - USD ($)	6 Months Ended
	Jun. 30, 2022	Jun. 30, 2021	Dec. 31, 2021
Goodwill and Intangible Assets Disclosure [Abstract]
Goodwill	$ 480,200		$ 0
Amortization of Intangible Assets	$ 1,441	$ 1,083

Schedule of Notes Payable, Rela

Schedule of Notes Payable, Related Party (Details) - USD ($)	Jun. 30, 2022	Dec. 31, 2021
Notes Payable - Robert Leitzman
Short-Term Debt [Line Items]
Notes Payable Related Parties Classified Current Gross	$ 2,000	$ 2,000
Notes Payable - Sandra Oman
Short-Term Debt [Line Items]
Notes Payable Related Parties Classified Current Gross	10,000	10,000
Notes Payable - Nicole Breen
Short-Term Debt [Line Items]
Notes Payable Related Parties Classified Current Gross	168,109
Notes Payable - Snell & Wilmer L.L.P
Short-Term Debt [Line Items]
Notes Payable Related Parties Classified Current Gross		309,700
Notes Payable - Patrick Brodnik
Short-Term Debt [Line Items]
Notes Payable Related Parties Classified Current Gross	500,000
Notes Payable 6 [Member]
Short-Term Debt [Line Items]
Notes Payable Related Parties Classified Current Gross	$ 240,000	$ 300,000

Schedule of Notes Payable (Deta

Schedule of Notes Payable (Details) - USD ($)	Jun. 30, 2022	Dec. 31, 2021
Short-Term Debt [Line Items]
Notes Payable, Current	$ 0	$ 65,607
Notes Payable - Snell & Wilmer L.L.P
Short-Term Debt [Line Items]
Notes Payable, Current	0	54,169
Notes Payable - Patrick Brodnik
Short-Term Debt [Line Items]
Notes Payable, Current	$ 0	$ 11,438

Notes Payable (Details Narrativ

Notes Payable (Details Narrative) - USD ($)	6 Months Ended
	Jun. 30, 2022	Jun. 30, 2021
Debt Disclosure [Abstract]
Interest Expense, Other Long-Term Debt	$ 697	$ 1,338

Commitments and Contingencies (

Commitments and Contingencies (Details Narrative) - USD ($)	Feb. 05, 2018	Jan. 19, 2018	Jun. 30, 2022	Dec. 31, 2021
Loss Contingencies [Line Items]
Operating Lease, Liability			$ 50,139
Operating Lease, Right-of-Use Asset			$ 50,139
William Martin V S Weed Inc [Member]
Loss Contingencies [Line Items]
Loss Contingency, Allegations		On January 19, 2018, the Company was sued in the United States District Court for the District of Arizona ( William Martin v. WEED, Inc.), Case No. 4:18-cv-00027-RM) by the listed Plaintiff. The Company was served with the Verified Complaint on January 26, 2018. The Complaint alleges claims for breach of contract-specific performance, breach of contract-damages, breach of the covenant of good faith and fair dealing, conversion, and injunctive relief. In addition to the Verified Complaint, the Company was served with an application to show cause for a temporary restraining order. The Verified Complaint alleges the Company entered into a contract with the Plaintiff on October 1, 2014 for the Plaintiff to perform certain consulting services for the Company in exchange for 500,000 shares of its common stock up front and an additional 700,000 shares of common stock to be issued on May 31, 2015. The Plaintiff alleges he completed the requested services under the agreement and received the initial 500,000 shares of common stock, but not the additional 700,000 shares. The request for injunctive relief asks the Court to Order the Company to issue the Plaintiff 700,000 shares of its common stock, and possibly include them in its Registration Statement on Form S-1, or, in the alternative, issue the shares and have them held by the Court pending resolution of the litigation, or, alternatively, sell the shares and deposit the sale proceeds in an account that the Court will control. The hearing on the Temporary Restraining Order occurred on January 29, 2018. On January 30, 2018, the Court issued its ruling denying the application for a Temporary Restraining Order. Currently, there is no further hearing scheduled in this matter. On February 13, 2018, the Company filed an Answer to the Verified Complaint and Counterclaim. On February 15, 2018, the Company filed a Motion to Dismiss the Verified Complaint. On February 23, 2018, the Company filed a Motion to Amend Counterclaim to add W. Martin’s wife, Joanna Martin as a counterdefendant. On March 9, 2018, William Martin filed a Motion to Dismiss the Counterclaim. On March 12, 2018, William Martin filed a Motion to Amend the Verified Complaint to, among other things, add claims against Glenn Martin and Nicole and Ryan Breen. On March 27, 2018, the Court granted both William Martin and WEED, Inc.’s Motions to Amend. On March 27, 2018, the Company filed an Amended Counterclaim adding Joanna Martin. On April 2, 2018, the Company filed a Motion to Amend our Counterclaim to add a breach of contract claim. On April 10, 2018, the Company filed an Answer to First Amended Verified Complaint. On April 23, 2018, Glenn Martin and Nicole and Ryan Breen filed their Answer to the First Amended Complaint. On May 31, 2018, the Court issued an Order: (a) granting the Company’s Motion to Dismiss thereby dismissing the Plaintiff’s claims for breach of the covenant of good faith and fair dealing and the claim for conversion, (b) denying William Martin’s Motion to Dismiss the counterclaim as to the claims for fraudulent concealment and fraudulent misrepresentation, but granting the Motion to Dismiss only as to the claim for fraudulent nondisclosure, and (c) granting the Company’s Motion to Amend its Counterclaim to add a breach of contract claim. On June 1, 2018, William Martin and his wife filed their Answer to the First Amended Counterclaim. On June 1, 2018, William Martin and his wife filed their Answer to the Second Amended Counterclaim. In addition to the above pleadings and motions, the parties have exchanged disclosure statements and served and responded to written discovery. The Company denies the Plaintiff’s allegations in the Verified Complaint in their entirety and plan to vigorously defend against this lawsuit. Due to the loss not being probable, no accrual has been recorded for the 700,000 shares of common stock the Plaintiff alleges he is owed under his agreement with the Company.
Travis Nelson V S Sangre Agro Tech L L C [Member]
Loss Contingencies [Line Items]
Loss Contingency, Allegations	Travis Nelson v. Sangre AgroTech, LLC, et al. (Huerfeno County Colorado District Court, Case No. 2018CV30003, filed on February 5, 2018). Mr. Travis Nelson, formerly a member of the subsidiary Sangre AgroTech, LLC, filed this action alleging wrongful discharge in retaliation for whistleblower activity purportedly related to insider trading, fraud and unlawful interstate transportation of plant genetics. After a motion to dismiss was granted in part, Mr. Nelson filed a second amended complaint asserting revised claims for breach of fiduciary duty, wrongful discharge, and violation of the Colorado organized crime control act. Mr. Nelson has alleged lost wages in the amount of $600,000, unspecified losses related to whistleblower allegations, plus costs and attorneys’ fees. In his initial disclosures, Mr. Nelson alleges damages of $10,000,000. On January 31, 2019, Mr. Nelson submitted an offer of judgement in the amount of $100,000. That offer was rejected by the Corporation. Court-ordered mediation was conducted on April 24, 2019, but the matter was not resolved. By order dated February 4, 2020, the court scheduled trial for October 5, 2020. The Corporation denies liability as to all claims. Inasmuch as an unfavorable outcome is neither probable nor remote within the meaning of the ABA Statement of Policy referred to in the last paragraph of this letter, we decline to express an opinion concerning the likely outcome of this matter or the liability of the Corporation, if any, associated therewith.

Business Combination (Details)

Business Combination (Details) - USD ($)	Jun. 30, 2022	May 02, 2022	Dec. 31, 2021
Business Acquisition [Line Items]
Goodwill	$ 480,200		$ 0
Hempirical Genetics L L C [Member]
Business Acquisition [Line Items]
Inventory		$ 82,000
Equipment		87,800
Total assets acquired		169,800
Goodwill		480,200
Total Consideration		$ 650,000

Business Combination (Details N

Business Combination (Details Narrative) - Hempirical Genetics L L C [Member]	May 02, 2022 USD ($)
Business Acquisition [Line Items]
Business Combination, Consideration Transferred, Equity Interests Issued and Issuable	$ 2,000,000
Business Combination, Consideration Transferred	$ 650,000

Stockholders_ Equity (Details N

Stockholders’ Equity (Details Narrative) - USD ($)	3 Months Ended		6 Months Ended	12 Months Ended
	Jun. 30, 2022	Mar. 31, 2022	Jun. 30, 2022	Dec. 31, 2021	Dec. 05, 2014
Accumulated Other Comprehensive Income (Loss) [Line Items]
Preferred Stock, Shares Authorized					20,000,000
Preferred Stock, Par or Stated Value Per Share					$ 0.001
Common Stock, Shares Authorized	200,000,000		200,000,000	200,000,000	200,000,000
Common Stock, Par or Stated Value Per Share	$ 0.001		$ 0.001	$ 0.001	$ 0.001
Stock Issued During Period, Value, New Issues	$ 10,000	$ 30,000	$ 40,000	$ 560,000
Stock Issued During Period, Value, Issued for Services	$ 193,600	$ 314,200	$ 457,800	$ 2,002,850
Common Stock [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Stock Issued During Period, Shares, New Issues	100,000	200,000	300,000	2,200,000
Stock Issued During Period, Value, New Issues	$ 100	$ 200		$ 2,200
Stock Issued During Period, Shares, Issued for Services	670,000	1,410,000	2,080,000	3,650,000
Stock Issued During Period, Value, Issued for Services	$ 670	$ 1,410		$ 3,650
Stock Issued During Period, Shares, Acquisitions	1,000,000		1,000,000

Common Stock Warrants and Opt_3

Common Stock Warrants and Options (Details) - Equity Option [Member] - $ / shares	6 Months Ended
	Jun. 30, 2022	Jun. 30, 2021
Offsetting Assets [Line Items]
Outstanding at the beginning of period	6,000,000	6,000,000
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price, Beginning Balance	$ 10.55	$ 10.55
Granted
Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Grants in Period, Weighted Average Exercise Price
Exercised/Expired/Cancelled
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures and Expirations in Period, Weighted Average Exercise Price
Outstanding at the end of period	6,000,000	6,000,000
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price, Ending Balance	$ 10.55	$ 10.55
Exercisable at the end of period	6,000,000	6,000,000
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Exercise Price	$ 10.55	$ 10.55

Common Stock Warrants and Opt_4

Common Stock Warrants and Options (Details Narrative)	12 Months Ended
	Dec. 31, 2020 shares
Warrant [Member]
Offsetting Assets [Line Items]
Share-Based Compensation Arrangement by Share-Based Payment Award, Non-Option Equity Instruments, Expirations	200,000

Income Tax (Details)

Income Tax (Details) - USD ($)	3 Months Ended			6 Months Ended		12 Months Ended
	Jun. 30, 2022	Mar. 31, 2022	Jun. 30, 2021	Jun. 30, 2022	Jun. 30, 2021	Dec. 31, 2021
Deferred tax assets:
Net operating loss carry forward as of 12/31/2021		$ 12,817,540		$ 12,817,540
Estimate Tax Loss June 30, 2022	$ (226,297)	$ 590,971	$ 1,227,763	364,674	$ 2,199,507	$ 2,841,850
Add back shares for services				(457,800)
NOL Carry Forward Cumulative as of 6/30/2022	12,724,414			$ 12,724,414		$ 12,817,540
Statutory Tax Rate				21%
Deferred Tax Asset	2,672,127			$ 2,672,127
Valuation	(2,672,127)			(2,672,127)
Net Deferred Tax Asset	$ 0			$ 0

Income Tax (Details Narrative)

Income Tax (Details Narrative) - USD ($)	6 Months Ended	12 Months Ended
	Jun. 30, 2022	Dec. 31, 2021
Income Tax Disclosure [Abstract]
Effective Income Tax Rate Reconciliation at Federal Statutory Income Tax Rate, Amount	$ 364,674	$ 2,683,947